StockNews.com Initiates Coverage on Pfizer (NYSE:PFE)

Equities research analysts at StockNews.com assumed coverage on shares of Pfizer (NYSE:PFE – Get Rating) in a report issued on Wednesday. The firm set a “strong-buy” rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on PFE. UBS Group set a $59.00 price target on Pfizer in a research report on Thursday, September 1st. Morgan Stanley cut their price objective on Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a research report on Friday, July 8th. JPMorgan Chase & Co. set a $50.00 price objective on Pfizer in a research report on Tuesday. Barclays set a $50.00 price objective on Pfizer in a research report on Thursday, September 1st. Finally, Berenberg Bank set a $44.00 price objective on Pfizer in a research report on Wednesday, September 14th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $56.33.

Pfizer Trading Up 0.4 %

Pfizer stock opened at $41.92 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.42 and a debt-to-equity ratio of 0.39. Pfizer has a 52 week low of $40.94 and a 52 week high of $61.71. The company has a market capitalization of $235.27 billion, a price-to-earnings ratio of 8.20, a price-to-earnings-growth ratio of 0.52 and a beta of 0.63. The stock has a 50-day moving average price of $46.43 and a 200 day moving average price of $49.53.

Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.75 by $0.29. The firm had revenue of $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The company’s revenue was up 46.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 earnings per share. Sell-side analysts anticipate that Pfizer will post 6.54 EPS for the current year. Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently modified their holdings of the company. Steward Financial Group LLC raised its holdings in shares of Pfizer by 315.3% in the 2nd quarter. Steward Financial Group LLC now owns 544 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 413 shares during the period. Rinkey Investments purchased a new stake in Pfizer during the 4th quarter worth about $32,000. Worth Asset Management LLC purchased a new stake in Pfizer during the 1st quarter worth about $29,000. Goodman Advisory Group LLC purchased a new stake in Pfizer during the 2nd quarter worth about $32,000. Finally, Stuart Chaussee & Associates Inc. increased its holdings in Pfizer by 108.3% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 325 shares during the period. Hedge funds and other institutional investors own 67.90% of the company’s stock.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Further Reading

Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.